The Yi lab research focuses on tumor immunology and tumor biology, with specific interests in understanding how myeloma cells develop drug resistance in the context of tumor microenvironment and in developing novel and effective immunotherapy strategies to treat myeloma and solid tumors
Ralph O’Connor Centennial Chair, Dr. Mary and Ron Neal Cancer Center Cancer Center
Professor of Oncology, Academic Institute
Full Member, Research Institute
Director, Center for Translational Research in Hematological Malignancies
Associate Director, Cancer Center Basic Research Programs, Cancer Center
Weill Cornell Medical College
Dr. Qing Yi is a trained medical immunologist with over 25 years of experience as a well-funded and published researcher. He is one of the leading investigators in the fields of tumor immunology and immunotherapy in multiple myeloma and other cancers.
Since arriving in the US in 1998, Dr. Yi has been awarded, as the PI, 9 R01s from NCI, 1 project and 1 core grant in the MDACC Myeloma SPORE (P50), 4 R01-type translational grants from the LLS, 4 Senior Researcher Awards from the MMRF, 2 K99/R00 grants (as the mentor), and numerous intramural and industry grants. Dr. Yi and colleagues have published more than 160 peer-reviewed research articles, with 45 being in top-tier journals with an impact factor of greater than 10.
Prior to his current appointment as Associate Director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center, Dr. Yi had faculty appointments at Lerner Research Institute at the Cleveland Clinic in Ohio, MD Anderson Cancer Center, University of Arkansas for Medical Sciences, and Karolinska Hospital and Institute, Sweden.